Cannabinoids show promise as anti-inflammatory and anti-fibrotic drugs through mechanisms different from traditional painkillers | Research

The takeaway

Multiple cannabinoids, including THC, CBD, and the synthetic ajulemic acid, demonstrate anti-inflammatory and anti-fibrotic properties through pathways distinct from NSAIDs, potentially offering a new class of treatments for chronic inflammation.

Read this if you want to understand how cannabinoids fight inflammation differently from traditional anti-inflammatory drugs.

Cannabinoids work through different anti-inflammatory mechanisms than NSAIDs, with fewer associated side effects

What the researchers found

The review surveyed anti-inflammatory actions across several cannabinoid categories. The phytocannabinoids THC, CBD, cannabichromene, and cannabinol all showed anti-inflammatory effects. Three approved synthetic preparations (nabilone, dronabinol, and Sativex) also demonstrated anti-inflammatory properties.

The most detailed discussion focused on ajulemic acid (AJA), a synthetic cannabinoid in phase 2 clinical trials that showed both anti-inflammatory and anti-fibrotic effects. The review proposed a mechanism involving PPAR-gamma activation and resolution of inflammation through specialized pro-resolving mediators.

Critically, cannabinoids as a class appear to work through different mechanisms than NSAIDs and are generally free from NSAID-associated adverse effects like gastrointestinal bleeding and cardiovascular risk.

Why it matters

Chronic inflammation underlies many diseases but current anti-inflammatory drugs carry significant side effects. The finding that cannabinoids work through entirely different pathways than NSAIDs, with a generally better safety profile, opens a new therapeutic avenue. The progression of ajulemic acid into clinical trials represents the most advanced effort to translate cannabinoid anti-inflammatory science into medicine.

The numbers in context

Ajulemic acid was in three phase 2 clinical trials at the time of publication. The review covered phytocannabinoids (THC, CBD, CBC, CBN), three synthetic preparations (nabilone, dronabinol, Sativex), and the endocannabinoid system.

How the study worked

Narrative review surveying published research on the anti-inflammatory and anti-fibrotic effects of phytocannabinoids, endocannabinoids, synthetic cannabinoids, and related lipoamino acids. Focused particularly on mechanism of action and clinical development status.

What this study cannot tell us

Narrative review without systematic methodology, so study selection may be incomplete. Much of the evidence comes from preclinical models. The clinical trial results for ajulemic acid were not yet available. The review was written by researchers involved in ajulemic acid development, representing a potential conflict of interest.

How to read the evidence

Narrative review synthesizing evidence from multiple studies. Provides a useful overview but lacks the rigor of a systematic review.

When this study was published

Published in 2016. Ajulemic acid (now called lenabasum) has since completed additional clinical trials with mixed results.

The bigger picture

The distinction between cannabinoid and NSAID mechanisms is important. Rather than broadly suppressing inflammation (which can impair healing), cannabinoids may promote its resolution through specialized pathways. This "pro-resolution" approach could treat chronic inflammatory conditions without compromising the body's ability to fight infection or heal wounds.

Questions still open

How did the ajulemic acid clinical trials ultimately perform? Can the anti-fibrotic properties of cannabinoids be harnessed for conditions like liver fibrosis or pulmonary fibrosis? Would combining cannabinoid and traditional anti-inflammatory approaches produce additive benefits?

Common questions

Could cannabinoids replace ibuprofen or aspirin?

The review suggests cannabinoids work through different pathways than NSAIDs, but it does not directly compare their effectiveness. Some synthetic cannabinoids are in clinical trials for specific inflammatory conditions. Whether they could serve as broad replacements for common painkillers remains to be determined.

What is fibrosis and how do cannabinoids affect it?

Fibrosis is the buildup of scar tissue in organs, often resulting from chronic inflammation. It can damage the liver, lungs, and other organs. The review found that certain cannabinoids can reduce fibrotic scarring, potentially by promoting the resolution of inflammation rather than just suppressing it.

Read the original research

Cannabinoids, inflammation, and fibrosis.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 30(11), 3682-3689

View on PubMed ↗

Citation

Zurier, Robert B; Burstein, Sumner H. (2016). Cannabinoids, inflammation, and fibrosis.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 30(11), 3682-3689.